From: Associated risk factors with disease severity and antiviral drug therapy in patients with COVID-19
Variables | All Patients (n = 550) | Severe (n = 178) | Non-severe (n = 372) | p value |
---|---|---|---|---|
Complications n, % | ||||
 Acute myocardial injury | 111(20.2%) | 76(42.7%) | 35(9.4%) | < 0.001 |
 Secondary infection | 110 (20.0%) | 82(46.1%) | 28(7.5%) | < 0.001 |
 ARDS | 69 (12.5%) | 69(38.8%) | 0 | < 0.001 |
 Acute kidney injury | 45 (8.2%) | 33(18.5%) | 12(3.2%) | < 0.001 |
 Shock | 40 (7.3%) | 39(21.9%) | 1(0.3%) | < 0.001 |
 DIC | 20(3.6%) | 11(6.2%) | 9(2.4%) | 0.028 |
Treatment n.% | ||||
 Antiviral therapy | 449 (81.6%) | 162(91.0%) | 287(77.2%) | < 0.001 |
 Antibacterial therapy | ||||
  one kind | 204 (37.1%) | 40(22.5%) | 164(44.1%) | < 0.001 |
   ≥ two kinds | 231(42.0%) | 136(76.4%) | 95(25.5%) | < 0.001 |
 Antifungal therapy | 10(1.8%) | 8(4.5%) | 2(0.5%) | 0.004 |
 Glucocorticoids therapy | 191(34.7%) | 122(68.5%) | 69(18.5%) | < 0.001 |
Immunotherapy | ||||
 Human immunoglobulin | 52(9.5%) | 23(12.9%) | 29(7.8%) | 0.055 |
 Thymosin | 10(1.8%) | 6(3.4%) | 4(1.1%) | 0.123 |
Vasoactive drug | 34(6.2%) | 34(19.1%) | 0 | < 0.001 |
 CRRT | 2(0.4%) | 2(1.1%) | 0 | 0.104 |
Respiratory support-no.% | ||||
 Nasal catheter/Mask oxygen | 477(86.8%) | 105(59.0%) | 372(100.0%) | < 0.001 |
 High-flow nasal cannula | 5 (0.9%) | 5(2.8%) | 0 | < 0.001 |
 Noninvasive ventilation | 32 (5.8%) | 32(18.0%) | 0 | < 0.001 |
 Invasive ventilation | 36 (6.5%) | 36(20.2%) | 0 | < 0.001 |
 ECMO | 0 | 0 | 0 | – |
prognosis-no.% | ||||
 Transfer | 24 (4.4%) | 16 (9.0%) | 8 (2.2%) | < 0.001 |
 Improved | 474 (86.1%) | 110 (61.8%) | 364 (97.8%) | < 0.001 |
 Death | 52(9.5%) | 52(29.2%) | 0 | < 0.001 |
     Multiple system and organ failure | 33/52 (63.5%) | 33/52 (63.5%) | – | – |
    Respiratory failure | 16/52 (30.8%) | 16/52 (30.8%) | – | – |
    Circulatory failure | 2/52 (3.8%) | 2/52 (3.8%) | – | – |
    Septic shock | 1/52 (1.9%) | 1/52 (1.9%) | – | – |
Negative conversion time of RNA Detection, Median (IQR)-days | 10 (6–16) | 13 (8–18) | 9 (6–16) | 0.016 |
Length of hospital stay, Median (IQR)-days | 16 (9–26) | 22 (13–30) | 15 (9–22.75) | < 0.001 |